Literature DB >> 22733832

Outcomes of pseudo-severe aortic stenosis under conservative treatment.

Emilie Fougères1, Christophe Tribouilloy, Mehran Monchi, Hélène Petit-Eisenmann, Serge Baleynaud, Agnès Pasquet, Christophe Chauvel, Damien Metz, Catherine Adams, Dan Rusinaru, Pascal Guéret, Jean-Luc Monin.   

Abstract

AIMS: In the setting of low-flow/low-gradient aortic stenosis (LF/LGAS), outcomes of pseudo-severe aortic stenosis (AS) remain poorly described. This study was aimed to assess the outcome of patients with pseudo-severe AS under conservative treatment. METHODS AND
RESULTS: Among 305 patients from the European Registry of LF/LGAS, the outcomes of the 107 patients followed under conservative treatment were analysed. Based on the results of dobutamine echocardiography, patients were divided into group IA [left ventricular (LV) contractile reserve present with true-severe AS, n = 43], group IB [pseudo-severe AS (n = 29) defined as LV contractile reserve with a final aortic valve area ≥1.2 cm(2) and a mean transaortic pressure gradient <40 mmHg at peak dobutamine infusion], or group II (exhausted LV contractile reserve, n = 35). The rate of death within 5 years was significantly lower in the group IB (43 ± 11%, n = 10), when compared with the group IA (91 ± 6%, n = 33; P = 0.001) and the group II (100%, n = 23; P < 0.001). The Cox proportional hazard model analysis demonstrated that the hazard ratio for death in the group IB remained significantly lower than in the other groups, even after adjustment for currently established risk factors. Furthermore, the 5-year survival of pseudo-severe AS patients was comparable with that of propensity-matched patients with systolic heart failure and no evidence of valve disease.
CONCLUSION: In patients with pseudo-severe AS, the 5-year survival under conservative treatment is better than in true-severe AS and comparable with that of propensity-matched patients with LV systolic dysfunction and no evidence of valve disease. Further studies are needed to define optimal therapeutic management in these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22733832     DOI: 10.1093/eurheartj/ehs176

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  19 in total

Review 1.  Evaluation of aortic stenosis: an update--including low-flow States, myocardial mechanics, and stress testing.

Authors:  Luc A Pierard; Raluca Dulgheru
Journal:  Curr Cardiol Rep       Date:  2015-06       Impact factor: 2.931

Review 2.  Low-flow/low-gradient aortic stenosis-Still a diagnostic and therapeutic challenge.

Authors:  Anja Vogelgesang; Gerd Hasenfuss; Claudius Jacobshagen
Journal:  Clin Cardiol       Date:  2017-05-23       Impact factor: 2.882

Review 3.  Low flow low gradient aortic stenosis: clinical pathways.

Authors:  I Sathyamurthy; K Jayanthi
Journal:  Indian Heart J       Date:  2014-11-20

4.  Assessment of Aortic Valve Disease: Role of Imaging Modalities.

Authors:  Romain Capoulade; Philippe Pibarot
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-11

5.  Low gradient aortic stenosis.

Authors:  Katie M Doucet; Ian G Burwash
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-05

Review 6.  Advanced imaging in valvular heart disease.

Authors:  Jeroen J Bax; Victoria Delgado
Journal:  Nat Rev Cardiol       Date:  2017-01-27       Impact factor: 32.419

Review 7.  Workup and Management of Patients With Paradoxical Low-Flow, Low-Gradient Aortic Stenosis.

Authors:  Mohamed-Salah Annabi; Marine Clisson; Marie-Annick Clavel; Philippe Pibarot
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-05-02

Review 8.  Low-gradient aortic stenosis.

Authors:  Marie-Annick Clavel; Julien Magne; Philippe Pibarot
Journal:  Eur Heart J       Date:  2016-03-31       Impact factor: 29.983

Review 9.  Paradoxical low flow aortic valve stenosis: incidence, evaluation, and clinical significance.

Authors:  Marie-Annick Clavel; Philippe Pibarot; Jean G Dumesnil
Journal:  Curr Cardiol Rep       Date:  2014-01       Impact factor: 2.931

Review 10.  Imaging of Valvular Heart Disease in Heart Failure.

Authors:  Tomaz Podlesnikar; Victoria Delgado; Jeroen J Bax
Journal:  Card Fail Rev       Date:  2018-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.